Impact of Ceftazidime / Avibactam Treatment vs Better Available Therapy on Mortality of Patients With Infections Caused by Carbapenem-resistant Enterobacteria

NCT04167228 · clinicaltrials.gov ↗

COMPLETED

Status

348

Enrollment

OTHER

Sponsor class

Conditions

Carbapenem-Resistant Enterobacteriaceae Infection

Interventions

DRUG: Ceftazidime-Avibactam
DRUG: Best Available Therapy

Sponsor

Maimónides Biomedical Research Institute of Córdoba